Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.
The companies also confirmed that they are planning a company-sponsored phase III study of Nexavar in the adjuvant treatment of hepatocellular carcinoma (HCC) following the complete removal of early stage liver cancer.
A previous clinical trial demonstrated that Nexavar extended overall survival by 44% in patients with HCC versus placebo.